|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
4
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rocha-Lima CM, Soares HP, Raez LE and
Singal R: EGFR targeting of solid tumors. Cancer Control.
14:295–304. 2007.PubMed/NCBI
|
|
6
|
Itakura Y, Sasano H, Shiga C, Furukawa Y,
Shiga K, Mori S and Nagura H: Epidermal growth factor receptor
overexpression in esophageal carcinoma. An immunohistochemical
study correlated with clinicopathologic findings and DNA
amplification. Cancer. 74:795–804. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li FC, Li YH, Zhao X, Fu WN, Xu ZM, Li ZG
and Sun KL: Association of homozygous deletion of p15 and p16 gene
and amplification of EGFR gene in laryngeal squamous cell
carcinoma. Yi Chuan Xue Bao. 31:109–113. 2004.(In Chinese).
PubMed/NCBI
|
|
8
|
Li F, Kang N, Fu W, Sun X, Gao H and Sun
K: Detection of epidermal growth factor receptor gene amplification
in human laryngeal carcinomas by means of fluorescence in situ
hybridization. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 17:278–280.
2000.(In Chinese). PubMed/NCBI
|
|
9
|
Moghal N and Sternberg PW: Multiple
positive and negative regulators of signaling by the EGF-receptor.
Curr Opin Cell Biol. 11:190–196. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prewett M, Rockwell P, Rockwell RF,
Giorgio NA, Mendelsohn J, Scher HI and Goldstein NI: The biologic
effects of C225, a chimeric monoclonal antibody to the EGFR, on
human prostate carcinoma. J Immunother Emphasis Tumor Immunol.
19:419–427. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matar P, Rojo F, Cassia R, Moreno-Bueno G,
Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J,
Palacios J, et al: Combined epidermal growth factor receptor
targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and
the monoclonal antibody cetuximab (IMC-C225): Superiority over
single-agent receptor targeting. Clin Cancer Res. 10:6487–6501.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huether A, Höpfner M, Baradari V, Schuppan
D and Scherübl H: EGFR blockade by cetuximab alone or as
combination therapy for growth control of hepatocellular cancer.
Biochem Pharmacol. 70:1568–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galizia G, Lieto E, De Vita F, Orditura M,
Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab,
a chimeric human mouse anti-epidermal growth factor receptor
monoclonal antibody, in the treatment of human colorectal cancer.
Oncogene. 26:3654–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kohrt HE, Colevas AD, Houot R, Weiskopf K,
Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira
R, et al: Targeting CD137 enhances the efficacy of cetuximab. J
Clin Invest. 124:2668–2682. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le Tourneau C and Siu LL:
Molecular-targeted therapies in the treatment of squamous cell
carcinomas of the head and neck. Curr Opin Oncol. 20:256–263. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Chen P, Fan QX and Wang R:
Clinical efficacy for the treatment of esophageal cancer with
rabdosia rubescens alone and combining with chemotherapy. Life Sci
J. 4:22–25. 2007.
|
|
17
|
Wang R and Wang L: Efficacy of Rabdosia
rubescens in treating 95 cases with esophageal and gastric cardiac
cancer. Cancer Res Prev Treat. 11:86–87. 1994.
|
|
18
|
Kuo LM, Kuo CY, Lin CY, Hung MF, Shen JJ
and Hwang TL: Intracellular glutathione depletion by oridonin leads
to apoptosis in hepatic stellate cells. Molecules. 19:3327–3344.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Li X, Wang J, Ye Z and Li JC:
Oridonin up-regulates expression of P21 and induces autophagy and
apoptosis in human prostate cancer cells. Int J Biol Sci.
8:901–912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang CL, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin induced A375-S2 cell apoptosis via
bax-regulated caspase pathway activation, dependent on the
cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 6:127–138.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou GB, Chen SJ, Wang ZY and Chen Z: Back
to the future of oridonin: Again, compound from medicinal herb
shows potent antileukemia efficacies in vitro and in vivo. Cell
Res. 17:274–276. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kang N, Zhang JH, Qiu F, Tashiro S,
Onodera S and Ikejima T: Inhibition of EGFR signaling augments
oridonin-induced apoptosis in human laryngeal cancer cells via
enhancing oxidative stress coincident with activation of both the
intrinsic and extrinsic apoptotic pathways. Cancer Lett.
294:147–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin
A, Li X, Wu J and Tang X: Oxaliplatin activates the Keap1/Nrf2
antioxidant system conferring protection against the cytotoxicity
of anticancer drugs. Free Radic Biol Med. 70:68–77. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang DT, He J, Wu M, Li SM, Gao Q and Zeng
QP: Artemisinin mimics calorie restriction to trigger mitochondrial
biogenesis and compromise telomere shortening in mice. PeerJ.
3:e8222015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siegelin MD, Plescia J, Raskett CM,
Gilbert CA, Ross AH and Altieri DC: Networks for therapy of
glioblastoma global targeting of subcellular heat shock. Mol Cancer
Ther. 9:1638–1646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang D, Torres CM, Bardhan K, Zimmerman M,
McGaha TL and Liu K: Decitabine and vorinostat cooperate to
sensitize colon carcinoma cells to Fas ligand-induced apoptosis in
vitro and tumor suppression in vivo. J Immunol. 188:4441–4449.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiong Y, Hannon GJ, Zhang H, Casso D,
Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin
kinases. Nature. 366:701–704. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee WY, Liu KW and Yeung JH: Reactive
oxygen species-mediated kinase activation by dihydrotanshinone in
tanshinones-induced apoptosis in HepG2 cells. Cancer Lett.
285:46–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salcher S, Hagenbuchner J, Geiger K,
Seiter MA, Rainer J, Kofler R, Hermann M, Kiechl-Kohlendorfer U,
Ausserlechner MJ and Obexer P: C10ORF10/DEPP, a transcriptional
target of FOXO3, regulates ROS-sensitivity in human neuroblastoma.
Mol Cancer. 13:2242014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moon DO, Kim MO, Kang CH, Lee JD, Choi YH
and Kim GY: JNK inhibitor SP600125 promotes the formation of
polymerized tubulin, leading to G2/M phase arrest,
endoreduplication, and delayed apoptosis. Exp Mol Med. 41:665–677.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ciardiello F and Tortora G: A novel
approach in the treatment of cancer: Targeting the epidermal growth
factor receptor. Clin Cancer Res. 7:2958–2970. 2001.PubMed/NCBI
|
|
33
|
Balin-Gauthier D, Delord JP, Rochaix P,
Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P and Allal C: In
vivo and in vitro antitumor activity of oxaliplatin in combination
with cetuximab in human colorectal tumor cell lines expressing
different level of EGFR. Cancer Chemother Pharmacol. 57:709–718.
2006. View Article : Google Scholar
|
|
34
|
Park SJ, Kim MJ, Kim YK, Kim SM, Park JY
and Myoung H: Combined cetuximab and genistein treatment shows
additive anti-cancer effect on oral squamous cell carcinoma. Cancer
Lett. 292:54–63. 2010. View Article : Google Scholar
|
|
35
|
Zhang L, Li XF, Tand L, Zhao YM and Zhou
CC: The effects of cetuximab in combination with docetaxel for the
acquired resistance to EGFR-TKI in non-small cell lung cancer
cells. Tumor. 34:584–590. 2014.
|
|
36
|
Leeman-Neill RJ, Wheeler SE, Singh SV,
Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC,
Sen M, et al: Guggulsterone enhances head and neck cancer therapies
via inhibition of signal transducer and activator of
transcription-3. Carcinogenesis. 30:1848–1856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang YY, Lv YF, Lu L and Cai L: Oridonin
inhibits mTOR signaling and the growth of lung cancer tumors.
Anticancer Drugs. 25:1192–1200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y,
Li M, Mu J, Wu W, Ding Q, et al: Oridonin induces apoptosis and
cell cycle arrest of gallbladder cancer cells via the mitochondrial
pathway. BMC Cancer. 14:2172014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li D, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Oridonin inhibited the tyrosine kinase activity and
induced apoptosis in human epidermoid carcinoma A431 cells. Biol
Pharm Bull. 30:254–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao X, He Z, Cao W, Cai F, Zhang L, Huang
Q, Fan C, Duan C, Wang X, Wang J, et al: Oridonin inhibits
gefitinib-resistant lung cancer cells by suppressing
EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol.
48:2608–2618. 2016.PubMed/NCBI
|
|
41
|
Selvendiran K, Bratasz A, Tong L, Ignarro
LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin,
inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in
cisplatin-resistant human ovarian cancer cells and xenografts. Cell
Cycle. 7:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iwase M, Takaoka S, Uchida M, Yoshiba S,
Kondo G, Watanabe H, Ohashi M and Nagumo M: Epidermal growth factor
receptor inhibitors enhance susceptibility to Fas-mediated
apoptosis in oral squamous cell carcinoma cells. Oral Oncol.
44:361–368. 2008. View Article : Google Scholar
|
|
43
|
Kriegs M, Gurtner K, Can Y, Brammer I,
Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, et al:
Radiosensitization of NSCLC cells by EGFR inhibition is the result
of an enhanced p53-dependent G1 arrest. Radiother Oncol.
115:120–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang N, Zhang JH, Qiu F, Chen S, Tashiro
S, Onodera S and Ikejima T: Induction of G2/M phase
arrest and apoptosis by oridonin in human laryngeal carcinoma
cells. J Nat Prod. 73:1058–1063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo
ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces
apoptosis and senescence in colorectal cancer cells by increasing
histone hyperacetylation and regulation of p16, p21, p27 and c-myc.
BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hsieh TC, Wijeratne EK, Liang JY,
Gunatilaka AL and Wu JM: Differential control of growth, cell cycle
progression, and expression of NF-kappaB in human breast cancer
cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin,
diter-penoids from the chinese herb Rabdosia rubescens. Biochem
Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tandon M, Salamoun JM, Carder EJ, Farber
E, Xu S, Deng F, Tang H, Wipf P and Wang QJ: SD-208, a novel
protein kinase D inhibitor, blocks prostate cancer cell
proliferation and tumor growth in vivo by inducing G2/M cell cycle
arrest. PLoS One. 10:e01193462015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Clerkin JS, Naughton R, Quiney C and
Cotter TG: Mechanisms of ROS modulated cell survival during
carcinogenesis. Cancer Lett. 266:30–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S,
Onodera S and Ikejima T: Autophagy inhibits reactive oxygen
species-mediated apoptosis via activating p38-nuclear factor-kappa
B survival pathways in oridonin-treated murine fibrosarcoma L929
cells. FEBS J. 276:1291–1306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li JP, Yang YX, Liu QL, Pan ST, He ZX,
Zhang X, Yang T, Chen XW, Wang D, Qiu JX, et al: The
investigational Aurora kinase A inhibitor alisertib (MLN8237)
induces cell cycle G2/M arrest, apoptosis, and autophagy via p38
MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Drug Des Devel Ther. 9:1627–1652. 2015.PubMed/NCBI
|
|
51
|
Sánchez-Pérez I, Martínez-Gomariz M,
Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK
activation and apoptosis in response to cisplatin. Oncogene.
19:5142–5152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pereira L, Igea A, Canovas B, Dolado I and
Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to
cisplatin-induced apoptosis mediated by reactive oxygen species and
JNK. EMBO Mol Med. 5:1759–1774. 2013. View Article : Google Scholar : PubMed/NCBI
|
